Abstract. Prostate cancer (PCa) is one of the most frequently diagnosed types of cancer worldwide. However, there remains a lack of accurate biomarkers to predict the outcome of PCa. Non-SMC condensin I complex subunit H (NCAPH) encodes a regulatory subunit of the non-structural maintenance of chromosomes condensin I complex. The present study aimed to investigate whether NCAPH may be a novel diagnostic marker for PCa by analyzing public datasets, including GSE17951, GSE55945 and a dataset from The Cancer Genome Atlas. The current results, to the best of our knowledge, demonstrated for the first time that NCAPH is significantly upregulated in PCa. Furthermore, it was identified that NCAPH expression is higher in stage T3/T4 and N1 PCa samples compared with stage T2 and N0 PCa samples, respectively. Kaplan-Meier analysis demonstrated that overexpression of NCAPH is associated with poor survival of patients with PCa. Bioinformatics analysis revealed that NCAPH is involved in regulating the PCa cell cycle by interacting with a number of proteins, including non-SMC condensin I complex subunit D2, non-SMC condensin I complex subunit G, structural maintenance of chromosomes 4, structural maintenance of chromosomes 2, Aurora kinase A, Aurora kinase B, cyclin-dependent kinase 1, H2A histone family member Z, POC1 centriolar protein A and histone cluster 2 H2A family member C. In summary, the present results suggest NCAPH may be a novel and beneficial diagnostic and therapeutic target in PCa.
Introduction
Condensin serves crucial roles in chromosome-wide gene regulation by controlling sister chromatid cohesion and separation in mitotic and meiotic cell cycles of all proliferative cells (1, 2) . Structural maintenance of chromosomes (SMC) proteins and three non-SMC subunits, including non-SMC condensin I complex subunit H (NCAPH), subunit I (NCAPG) and subunit D2 (NCAPD2) form the condensin I complex (3) . Previous studies have reported that abnormal expression of the non-SMC condensin I complex is involved in the progression of human cancer (4) (5) (6) . For example, NCAPG is upregulated and serves as a regulator by regulating hepatocellular cancer cell proliferation and migration (4, 7) . To the best of our knowledge, no previous study has revealed the prognostic value and the functional roles of the non-SMC condensin I complex in prostate cancer (PCa).
PCa is one of the most commonly diagnosed malignant cancer types in males worldwide (8) , including in China (9) . Although several important prognostic indicators, including prostate-specific antigen level, Gleason Score and TNM stage, have widely been used in the diagnosis of PCa (10, 11) , there remains an urgent requirement to develop novel prognostic biomarkers for PCa. NCAPH is associated with mitotic chromosomes (12) and encodes a regulatory subunit of the non-SMC condensin I complex, which is required for the conversion of interphase chromatin into condensed chromosomes (13) . Viera et al (14) identified that NCAPH is localized to the chromosome axis with enrichment at the centromere and telomeric ends. Ryu et al (6) reported that NCAPH is upregulated in melanoma progression. In human colon cancer, Yin et al (5) demonstrated that NCAPH is overexpressed in tumor samples and knockdown of NCAPH significantly inhibited colon cancer cell proliferation in vitro and in vivo. These results suggest NCAPH could be an important diagnostic biomarker and prognostic indicator for cancer. However, the clinical relevance and functional roles of NCAPH in PCa remain unclear.
The aim of the present study was to investigate whether NCAPH may be a novel diagnostic marker and therapeutic target for PCa. The expression pattern of NCAPH was evaluated in PCa tissues and the associations between NCAPH and the clinical features of patients with PCa, including age, pathological stage and overall survival, were evaluated using The Cancer Genome Atlas (TCGA) data. The current study may provide useful information to promote the understanding of the clinical importance of NCAPH in prostate carcinogenesis. (15) .
The expression levels of NCAPH were downloaded as TCGA data from cBioPortal (http://www.cbioportal. org/) (16) . The TCGA PCa dataset was analyzed to evaluate the expression pattern of NCAPH in PCa samples. A total of 38 normal and 497 PCa samples were included in this dataset. Normal prostate tissue samples analyzed from the TGCA cohort were obtained from the marginal area of tumours derived from the same patient and were therefore paired samples. The median age of the patients in the TCGA PCa dataset was 62 years (range, 41-78 years). NCAPH protein expression levels in the PCa tissues and normal prostate tissues were reviewed using the Human Protein Atlas (http://www.proteinatlas.org/) (17) .
Microarray data. Three public datasets GSE21034 (18), GSE17951 (19) and GSE55945 (20) were download from the Gene Expression Omnibus (GEO) database (www.ncbi.nlm. nih.gov/geo/). GSE21034 (Taylor dataset) was reported by Taylor et al (18) and includes 370 PCa tissue samples and cell line samples. The GSE17951 dataset was reported by Jia et al (19) and contains 70 normal prostate and 67 PCa samples. The GSE55945 dataset was reported by Arredouani et al (20) and contains eight normal prostate and 13 PCa samples. unfortunately, the clinicopathological features of the patients were not available in the three GEO datasets. Genes with a fold-change ≥2 and P<0.05 were considered to be significantly differentially expressed.
Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.
To identify functions of NCAPH in PCa, GO functional enrichment analysis was performed for three functional ontologies: Biological process, cellular component and molecular function. KEGG pathway enrichment analysis was also performed to identify pathways enriched in PCa using the Database for Annotation, Visualization and Integrated Discovery (DAVID; https://david. ncifcrf.gov/home.jsp) (21) . The P-value was calculated by hypergeometric distribution, and a pathway with P<0.05 was considered as significant.
Protein-protein interaction (PPI) network construction. using a NCAPH interacting proteins dataset which was download from NCBI (https://www.ncbi.nlm.nih.gov/gene/23397), a total of 51 candidate proteins were identified. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; string-db.org/) database is a pre-computed global resource for the investigation and analysis of associations between proteins (22) . STRING was used to analyze the interactions between NCAPH-associated proteins, which were visualized with PPI networks. In the present study, only experimentally validated interactions with a combined score ≥0.4 were selected as significant. PPI networks were constructed using Cytoscape 3.6.1 software (http://www.cytoscape.org/) (23) .
Statistical analysis. SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for all statistical analysis. Pearson's χ 2 test and Fisher's exact test were used to analyze the associations of NCAPH expression with clinicopathological characteristics. Paired and independent Student's t-tests were used to compare continuous variables in two groups. Receiver operating curve (ROC) analysis was performed for evaluation of the specificity and sensitivity of NCAPH expression levels for discriminating patients with PCa from normal patients. Associations between continuous variables and categorical variables were evaluated using Mann Whitney u tests for two groups. Kaplan-Meier and Cox regression analyses were utilized to assess the associations between NCAPH and overall survival, as well as the prognosis of patients with PCa. A log-rank test was used to compare differences in survival times. All tests were two-sided and P<0.05 was considered to indicate a statistically significant difference. All numerical data are presented as the mean ± standard deviation of at least three independent experiments.
Results

NCAPH is upregulated in PCa.
The expression patterns of NCAPH in ten types of human cancer types, including BRCA, HNSC, COAD, KIRC, LIHC, LuSC, LuAD, KIRP, STAD and PCa, were analyzed. It was identified that NCAPH was significantly overexpressed in cancer tissues compared with normal samples (Figs. 1A-I and 2A), which suggests that NCAPH serves as an oncogene in human cancer. The present study then focused on the clinical roles of NCAPH in PCa.
As presented in Fig. 2A and B and Table I , TCGA analysis demonstrated that NCAPH was upregulated in PCa tissues compared with non-tumor tissues. In addition, it was identified that NCAPH could serve as a specific and sensitive biomarker for PCa (area under the curve, 0.769; 95% confidence interval, 0.701-0.836; P<0.0001; Fig. 2C ). To further validate this result, two independent public datasets GSE17951 (24) and GSE55945 (20) were analyzed. NCAPH was revealed to be overexpressed in PCa compared with normal samples in the GSE17951 dataset (P<0.001; Fig. 2D ) and the GSE55945 dataset (P<0.05; Fig. 2E ).
NCAPH is associated with pathological stage in PCa.
The possible prognostic values of NCAPH were then evaluated using TCGA RNA-seq data. Associations between NCAPH mRNA expression and the clinicopathological characteristics of PCa are summarized in Table II . Positive expression of NCAPH was associated with age ( Fig. 3A ; Table II ) and pathological stage ( Fig. 3B and C ; Table II ). As presented in Fig. 3 , NCAPH expression was significantly upregulated in T3/T4 PCa samples compared with T2 samples (Fig. 3B ) and in N1 stage PCa samples compared with N0 samples (Fig. 3C) . However, univariate analysis indicated that age, T stage and N stage were not associated with overall survival in PCa (Table III) . These results indicate that NCAPH is associated with the pathological stage of PCa.
Upregulation of NCAPH predicts a poor prognosis in PCa.
Furthermore, Kaplan-Meier analysis was performed to determine whether NCAPH expression is significantly associated with overall survival of patients with PCa. Two independent public datasets were analyzed, including the Taylor dataset (18) and TCGA dataset. The median NCAPH mRNA expression level in PCa tissues was used as the cut-off point to divide all cases into NCAPH-high (Taylor dataset, n=71; TCGA dataset, n=248) and NCAPH-low (Taylor dataset, n=71; TCGA dataset, n=247) groups. The samples with NCAPH expression higher than median value were identified as NCAPH-high, and the samples with NCAPH expression lower than median value were identified as NCAPH-low. In TCGA analysis, the overall survival rate was significantly higher in the NCAPH-low group compared with the NCAPH-high group (P=0.0012; Fig. 4A ). In addition, similar results were observed with the Taylor dataset (P=0.0099; Fig. 4B ). These results indicate that NCAPH expression could serve as a biomarker to predict the outcome of PCa.
Construction of NCAPH mediated PPI networks in PCa.
The molecular functions of NCAPH in PCa remain largely unclear. Therefore, the current study performed PPI network analysis to reveal the potential roles of NCAPH. using a NCAPH interacting proteins dataset which was download from NCBI (https://www.ncbi.nlm.nih.gov/gene/23397), a total of 51 candidate proteins were identifed. By applying STRING analysis, 10 of the 51 proteins [NCAPG, NCAPD2, structural maintenance of chromosomes 4 (SMC4), structural maintenance of chromosomes 2 (SMC2), Aurora kinase A (AuRKA), Aurora kinase B (AuRKB), cyclin-dependent kinase 1 (CDK1), H2A histone family member Z (H2AFZ), POC1 centriolar protein A (POC1A) and histone cluster 2 H2A family member C (HIST2H2AC)] were identified to interact with NCAPH with a combined score ≥0.4 and selected as seed genes.
PPI networks were then generated with the NCAPH interacting seed genes by applying STRING analysis. A total of 417 single nodes and 10,071 edges were included in the NCAPH-mediated PPI network. According to a previous study (25) , the 'K value' of the PPI network was calculated to identify the hub networks in PCa. Finally, a total of six hub networks were revealed. As presented in Fig. 5 , hub-network 1 contained 62 nodes and 1,325 edges (Fig. 5A) , hub-network 2 consisted of 57 nodes and 627 edges (Fig. 5B) , hub-network 3 contained 55 nodes and 418 edges (Fig. 5C ), hub-network 4 consisted of 17 nodes and 57 edges (Fig. 5D ), hub-network 5 included six nodes and 15 edges (Fig. 5E ) and hub-network 6 was composed of 25 nodes and 65 edges (Fig. 5F ).
NCAPH expression level -------------------------------
Enrichment analysis of NCAPH in PCa.
To investigate the biological characteristics of NCAPH in PCa, enrichment analysis based on the GO annotation system was performed.
A total of 417 genes in the NCAPH-mediated PPI network were classified according to GO terms using DAVID. GO analysis demonstrated that NCAPH is predominantly involved in regulating PCa cell cycle progression and cell proliferation (Fig. 6A) . A series of associated biological process terms, including 'Cell division', 'Mitotic nuclear division', 'G2/M transition of mitotic cell cycle', 'G1/S transition of mitotic cell cycle', 'Nucleosome assembly', 'DNA repair', 'Negative regulation of gene expression, epigenetic', 'DNA replication' and 'Sister chromatid cohesion' were enriched in GO analysis. Molecular function analysis demonstrated NCAPH is associated with 'Protein binding', 'Histone binding' and 'Chromatin binding' (Fig. 6B ). Furthermore, KEGG analysis revealed NCAPH is significantly associated with 'Cell cycle', 'Viral carcinogenesis', 'Alcoholism', 'Oocyte meiosis', 'p53 signaling pathway', 'Epstein-Barr virus infection', 'Systemic lupus erythematosus', 'MicroRNAs in cancer', 'Progesterone-mediated oocyte maturation' and 'Prostate cancer' (Fig. 6C) .
Discussion
PCa is one of the most frequently diagnosed cancer types worldwide (8, 26) . However, to the best of our knowledge, there remains a lack of accurate biomarkers to predict the outcome of PCa. The present study identified that NCAPH is significantly upregulated in tumor samples and could serve as a biomarker for PCa (14) . To reveal the potential roles of NCAPH in PCa, NCAPH-mediated PPI networks were constructed. Bioinformatics analysis was also performed to predict the potential functional roles of NCAPH in PCa.
NCAPH, NCAPG and NCAPD2 form the non-SMC condensin I complex, which serves crucial roles in chromosome-wide gene regulation in mitotic and meiotic cell cycles by controlling chromosome organization (1) . Previous studies have indicated the important roles of the condensin I complex in human cancer (4-6). NCAPH has been reported to be upregulated in melanoma and colon cancer (5, 6 ). The present study demonstrated that NCAPH is upregulated in PCa samples by analyzing three public datasets, including TCGA data, GSE17951 and GSE55945. In addition, it was identified that NCAPH is upregulated in T3/T4 PCa samples compared with T2 samples and upregulated in N1 stage PCa samples compared with N0 samples. Furthermore, Kaplan-Meier analysis revealed that patients with PCa with low NCAPH expression exhibited longer overall survival times compared with patients with high NCAPH expression. The present analysis was similar to a previous study regarding human colon cancer (5). Yin et al (5) also observed that NCAPH expression is higher in colon cancer tissues compared with adjacent normal tissues. However, the higher NCAPH expression in colon cancer was associated with an improved prognosis and longer survival time. One limitation of the current study should be noted; the detailed clinical information of the patients in the four public datasets was not completed. To the best of our knowledge, the present study reported for the first time that NCAPH is associated with the prognosis of PCa.
A number of studies have demonstrated that oncogenes or tumor-suppressive genes cooperate in interconnected pathways and molecular networks at different levels to regulate cancer progression (27, 28) . The present study constructed a NCAPH-mediated PPI network to reveal the associations of NCAPH in PCa, which included 417 single nodes and 10,071 edges. Abnormal cell cycle progression is a hallmark of human cancer (29, 30) . Therefore, targeting cell-cycle checkpoints could provide novel strategies for cancer treatment. Notably, GO and KEGG analysis revealed that NCAPH predominantly participates in regulating the PCa cell cycle and proliferation by affecting a series of associated biological processes, including cell division, mitotic nuclear division, G2/M transition of mitotic cell cycle and G1/S transition of mitotic cell cycle. Of note, Yin et al (5) also demonstrated that knockdown of NCAPH could induce cell cycle arrest at the G2/M phase. The present study together with other previous studies indicate that NCAPH-mediated cell cycle regulation is a mechanism involved in PCa proliferation. These results suggest NCAPH may be a therapeutic target for PCa.
In conclusion, the present study demonstrated for the first time that NCAPH was significantly upregulated in PCa. Furthermore, Kaplan-Meier analysis revealed that overexpression of NCAPH is associated with poor survival of patients with PCa. Bioinformatics analysis revealed NCAPH is involved in regulating PCa cell cycle by interacting with ten proteins, including NCAPD2, NCAPG, SMC4, SMC2, AuRKA, AuRKB, CDK1, H2AFZ, POC1A, HIST2H2AC. In summary, the current results suggest NCAPH may be a potential beneficial and novel diagnostic and therapeutic marker in PCa.
